There is no current preclinical or clinical data for ALK monotherapy activity in pediatric MPNST and EGFR and ALK targeting could potentially encounter therapy resistance due to NF1 and SUZ12 loss-of- function mutations14. Here, SUZ12 is linked to malignant peripheral nerve sheath tumor.